Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
PLEGRIDY™ (peginterferon beta-1a) two-year data confirm maintenance of efficacy and safety in multiple sclerosis patients
Assessing the potential impact of non-proprietary drug copies on quality of medicine and treatment in patients with relapsing multiple sclerosis: the experience with fingolimod.
Immunohistochemical detection of sphingosine-1-phosphate and sphingosine kinase-1 in human tissue samples.
Evaluation of the 2010 McDonald multiple sclerosis criteria in children with a clinically isolated syndrome.
Incidence of Mood or Anxiety Disorders in Children of Parents with Multiple Sclerosis.
Toso controls encephalitogenic immune responses by dendritic cells and regulatory T cells.
The Impact of Lesion In-Painting and Registration Methods on Voxel-Based Morphometry in Detecting Regional Cerebral Gray Matter Atrophy in Multiple Sclerosis.
Autoinflammatory grey matter lesions in humans: cortical encephalitis, clinical disorders, experimental models.
Treating multiple sclerosis with monoclonal antibodies: a 2013 update.
Dalfampridine Effects Beyond Walking Speed in Multiple Sclerosis.
Outcome and survival of asymptomatic PML in natalizumab-treated MS patients.
Ocular Findings in Alemtuzumab (Campath-1H)-induced Thyroid Eye Disease.
Is it time for a new global classification of multiple sclerosis?
No association between chronic cerebrospinal venous insufficiency and pediatric-onset multiple sclerosis.
FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system.
Treatment of facial myokymia in multiple sclerosis with botulinum toxin.
Ampyra 10mg beats 5mg, but weak overall results net neutral for ACOR
Regulatory T, natural killer T and γδ T cells in multiple sclerosis and chronic fatigue syndrome/myalgic encephalomyelitis: a comparison.
Brain parenchymal damage in neuromyelitis optica spectrum disorder - A multimodal MRI study.
Characterization of autologous mesenchymal stem cell-derived neural progenitors as a feasible source of stem cells for central nervous system applications in multiple sclerosis.
DemTect, PANDA, EASY, and MUSIC: Cognitive Screening Tools with Age Correction and Weighting of Subtests According to Their Sensitivity and Specificity.
Human iPSC-derived oligodendrocyte progenitor cells can myelinate and rescue a mouse model of congenital hypomyelination.
How Natalizumab Binds and Antagonizes α4 Integrins.
Huperzine A ameliorates experimental autoimmune encephalomyelitis via the suppression of T cell-mediated neuronal inflammation in mice.
Building a better sphingosine kinase-1 inhibitor.
Pages
« first
‹ previous
…
165
166
167
168
169
170
171
172
173
…
next ›
last »